Vitamin D supplements may reduce the risk of major cardiovascular events such as heart attacks among people aged over 60, finds a clinical trial published by The BMJ today.
Alcon’s dry eye drug achieves primary endpoints in Phase III trials
Share this article AR-15512 is a transient receptor potential melastatin 8 (TRPM8) agonist, which was added to Alcon’s portfolio following the acquisition of Aerie Pharmaceuticals